The next therapeutic challenge in HIV: polypharmacy

E Jennifer Edelman, Kirsha S Gordon, Janis Glover, Ian R McNicholl, David A Fiellin, Amy C Justice, E Jennifer Edelman, Kirsha S Gordon, Janis Glover, Ian R McNicholl, David A Fiellin, Amy C Justice

Abstract

With the adoption of combination antiretroviral therapy (ART), most HIV-infected individuals in care are on five or more medications and at risk of harm from polypharmacy, a risk that likely increases with number of medications, age, and physiologic frailty. Established harms of polypharmacy include decreased medication adherence and increased serious adverse drug events, including organ system injury, hospitalization, geriatric syndromes (falls, fractures, and cognitive decline) and mortality. The literature on polypharmacy among those with HIV infection is limited, and the literature on polypharmacy among non-HIV patients requires adaptation to the special issues facing those on chronic ART. First, those aging with HIV infection often initiate ART in their 3rd or 4th decade of life and are expected to remain on ART for the rest of their lives. Second, those with HIV may be at higher risk for age-associated comorbid disease, further increasing their risk of polypharmacy. Third, those with HIV may have an enhanced susceptibility to harm from polypharmacy due to decreased organ system reserve, chronic inflammation, and ongoing immune dysfunction. Finally, because ART is life-extending, nonadherence to ART is particularly concerning. After reviewing the relevant literature, we propose an adapted framework with which to address polypharmacy among those on lifelong ART and suggest areas for future work.

Figures

Fig. 1
Fig. 1
Veterans Aging Cohort Study: median number of daily long-term medications by HIV status and age. Thin black bar indicates the corresponding 95 % confidence interval
Fig. 2
Fig. 2
Optimizing medication prescribing. ART antiretroviral therapy, VACS Veterans Aging Cohort Study

References

    1. Patterson SM, Hughes C, Kerse N, Cardwell Chris R, Bradley Marie C. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2012;(5):CD008165. .
    1. Hovstadius B, Petersson G. Factors leading to excessive polypharmacy. Clin Geriatr Med. 2012;28(2):159–172. doi: 10.1016/j.cger.2012.01.001.
    1. Anthierens S, Tansens A, Petrovic M, Christiaens T. Qualitative insights into general practitioners views on polypharmacy. BMC Fam Pract. 2010;11:65. doi: 10.1186/1471-2296-11-65.
    1. Hughes LD, McMurdo ME, Guthrie B. Guidelines for people not for diseases: the challenges of applying UK clinical guidelines to people with multimorbidity. Age Ageing. 2013;42(1):62–69. doi: 10.1093/ageing/afs100.
    1. Lugtenberg M, Burgers JS, Westert GP. Effects of evidence-based clinical practice guidelines on quality of care: a systematic review. Qual Saf Health Care. 2009;18(5):385–392. doi: 10.1136/qshc.2008.028043.
    1. Moen J, Norrgard S, Antonov K, Nilsson JL, Ring L. GPs’ perceptions of multiple-medicine use in older patients. J Eval Clin Pract. 2010;16(1):69–75. doi: 10.1111/j.1365-2753.2008.01116.x.
    1. Shah BM, Hajjar ER. Polypharmacy, adverse drug reactions, and geriatric syndromes. Clin Geriatr Med. 2012;28(2):173–186. doi: 10.1016/j.cger.2012.01.002.
    1. Salazar JA, Poon I, Nair M. Clinical consequences of polypharmacy in elderly: expect the unexpected, think the unthinkable. Expert Opin Drug Saf. 2007;6(6):695–704.
    1. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med. 2007;146(2):87–95. doi: 10.7326/0003-4819-146-2-200701160-00003.
    1. Palella FJ, Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43(1):27–34. doi: 10.1097/01.qai.0000233310.90484.16.
    1. The Antiretroviral Therapy Cohort Collaboration Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372(9635):293–299. doi: 10.1016/S0140-6736(08)61113-7.
    1. Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011;53(11):1130–1139. doi: 10.1093/cid/cir626.
    1. Krentz HB, Cosman I, Lee K, Ming JM, Gill MJ. Pill burden in HIV infection: 20 years of experience. Antivir Ther. 2012;17(5):833–840. doi: 10.3851/IMP2076.
    1. Steinman MA, Hanlon JT. Managing medications in clinically complex elders: “There’s got to be a happy medium”. JAMA. 2010;304(14):1592–1601. doi: 10.1001/jama.2010.1482.
    1. Schiff GD, Galanter WL, Duhig J, Lodolce AE, Koronkowski MJ, Lambert BL. Principles of conservative prescribing. Arch Intern Med. 2011;171(16):1433–1440. doi: 10.1001/archinternmed.2011.256.
    1. Scott IA, Gray LC, Martin JH, Mitchell CA. Minimizing inappropriate medications in older populations: a 10-step conceptual framework. Am J Med. 2012;125(6):529–37.e4.
    1. Workgroup for HIV and Aging Consensus Project. Recommended treatment strategies for clinicians managing older patients with HIV. 2011.
    1. Hanna DB, Selik RM, Tang T, Gange SJ. Disparities among US states in HIV-related mortality in persons with HIV infection, 2001–2007. AIDS. 2012;26(1):95–103. doi: 10.1097/QAD.0b013e32834dcf87.
    1. High KP, Brennan-Ing M, Clifford DB, Cohen MH, Currier J, Deeks SG, et al. HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr. 2012;60(Suppl 1):S1–S18. doi: 10.1097/QAI.0b013e31825a3668.
    1. Justice AC. HIV and aging: time for a new paradigm. Curr HIV/AIDS Rep. 2010;7(2):69–76. doi: 10.1007/s11904-010-0041-9.
    1. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 2009;338:a3172. doi: 10.1136/bmj.a3172.
    1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2012.
    1. Gilbert Welch H, Schwartz L, Woloshin S. Overdiagnosed: making people sick in the pursuit of health. Boston: Beacon Press; 2011.
    1. Joshi D, O’Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet. 2011;377(9772):1198–1209. doi: 10.1016/S0140-6736(10)62001-6.
    1. Lucas GM, Mehta SH, Atta MG, Kirk GD, Galai N, Vlahov D, et al. End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004. AIDS. 2007;21(18):2435–2443. doi: 10.1097/QAD.0b013e32827038ad.
    1. Medapalli RK, Parikh CR, Gordon K, Brown ST, Butt AA, Gibert CL, et al. Comorbid diabetes and the risk of progressive chronic kidney disease in HIV-infected adults: data from the Veterans Aging Cohort Study. J Acquir Immune Defic Syndr. 2012;60(4):393–399. doi: 10.1097/QAI.0b013e31825b70d9.
    1. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis. BMC Public Health. 2012;12:234. doi: 10.1186/1471-2458-12-234.
    1. Nguyen GC, Sam J, Thuluvath PJ. Hepatitis C is a predictor of acute liver injury among hospitalizations for acetaminophen overdose in the United States: a nationwide analysis. Hepatology. 2008;48(4):1336–1341. doi: 10.1002/hep.22536.
    1. Prosperi MC, Fabbiani M, Fanti I, Zaccarelli M, Colafigli M, Mondi A, et al. Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study. BMC Infect Dis. 2012;12:296. doi: 10.1186/1471-2334-12-296.
    1. Lo Re V 3rd, Kostman JR, Amorosa VK. Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century. Clin Liver Dis. 2008;12(3):587–609, ix.
    1. Colley CA, Lucas LM. Polypharmacy: the cure becomes the disease. J Gen Intern Med. 1993;8(5):278–283. doi: 10.1007/BF02600099.
    1. Jyrkka J, Enlund H, Lavikainen P, Sulkava R, Hartikainen S. Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. Pharmacoepidemiol Drug Saf. 2011;20(5):514–22.
    1. Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, et al. Adverse drug events in ambulatory care. N Engl J Med. 2003;348(16):1556–1564. doi: 10.1056/NEJMsa020703.
    1. Jyrkka J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S. Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging. 2009;26(12):1039–48.
    1. Marcum ZA, Amuan ME, Hanlon JT, Aspinall SL, Handler SM, Ruby CM, et al. Prevalence of unplanned hospitalizations caused by adverse drug reactions in older veterans. J Am Geriatr Soc. 2012;60(1):34–41. doi: 10.1111/j.1532-5415.2011.03772.x.
    1. Richardson K, Ananou A, Lafortune L, Brayne C, Matthews FE. Variation over time in the association between polypharmacy and mortality in the older population. Drugs Aging. 2011;28(7):547–560. doi: 10.2165/11592000-000000000-00000.
    1. Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65(9):989–995. doi: 10.1016/j.jclinepi.2012.02.018.
    1. Clay PG. Actual medication pill burden and dosing frequency in HIV-infected patients with undetectable viral loads. J Int Assoc Physicians AIDS Care (Chic) 2004;3(2):49–55. doi: 10.1177/154510970400300203.
    1. Furler MD, Einarson TR, Walmsley S, Millson M, Bendayan R. Polypharmacy in HIV: impact of data source and gender on reported drug utilization. AIDS Patient Care STDS. 2004;18(10):568–86.
    1. Nachega JB, Hsu AJ, Uthman OA, Spinewine A, Pham PA. Antiretroviral therapy adherence and drug–drug interactions in the aging HIV population. AIDS. 2012;26(Suppl 1):S39–S53. doi: 10.1097/QAD.0b013e32835584ea.
    1. Marzolini C, Elzi L, Gibbons S, Weber R, Fux C, Furrer H, et al. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV cohort study. Antivir Ther. 2010;15(3):413–423. doi: 10.3851/IMP1540.
    1. Guaraldi G, Menozzi M, Zona S, Garlassi E, Berti A, Rossi E, et al. Polypharmacology for polypathology in HIV infected patients. Antivi Ther. 2010;15:A31.
    1. Marzolini C, Back D, Weber R, Furrer H, Cavassini M, Calmy A, et al. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother. 2011;66(9):2107–2111. doi: 10.1093/jac/dkr248.
    1. Ajuoga E, Sansgiry SS, Ngo C, Yeh RF. Use/misuse of over-the-counter medications and associated adverse drug events among HIV-infected patients. Res Social Adm Pharm. 2008;4(3):292–301. doi: 10.1016/j.sapharm.2007.08.001.
    1. Littlewood RA, Vanable PA. Complementary and alternative medicine use among HIV-positive people: research synthesis and implications for HIV care. AIDS Care. 2008;20(8):1002–1018. doi: 10.1080/09540120701767216.
    1. Barry DT, Goulet JL, Kerns RK, Becker WC, Gordon AJ, Justice AC, et al. Nonmedical use of prescription opioids and pain in veterans with and without HIV. Pain. 2011;152(5):1133–1138. doi: 10.1016/j.pain.2011.01.038.
    1. Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006;194(1):11–19. doi: 10.1086/505147.
    1. Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378(9787):238–246. doi: 10.1016/S0140-6736(11)60936-7.
    1. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1: a randomized trial. Ann Intern Med. 2011;154(7):445–456. doi: 10.7326/0003-4819-154-7-201104050-00316.
    1. Gotuzzo E, Markowitz M, Ratanasuwan W, Smith G, Prada G, Morales-Ramirez JO, et al. Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004) J Acquir Immune Defic Syndr. 2012;61(1):73–77. doi: 10.1097/QAI.0b013e318263277e.
    1. Gebo KA. HIV and aging: implications for patient management. Drugs Aging. 2006;23(11):897–913. doi: 10.2165/00002512-200623110-00005.
    1. Gebo KA, Justice A. HIV infection in the elderly. Curr Infect Dis Rep. 2009;11(3):246–254. doi: 10.1007/s11908-009-0036-0.
    1. Reisler RB, Han C, Burman WJ, Tedaldi EM, Neaton JD. Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr. 2003;34(4):379–386. doi: 10.1097/00126334-200312010-00004.
    1. Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26(7):825–31.
    1. Laprise C, Baril JG, Dufresne S, Trottier H. Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up. Clin Infect Dis. 2013;56(4):567–75.
    1. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496–505. doi: 10.1086/655681.
    1. Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26(7):867–875. doi: 10.1097/QAD.0b013e328351f68f.
    1. Gellad WF, Grenard JL, Marcum ZA. A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. Am J Geriatr Pharmacother. 2011;9(1):11–23. doi: 10.1016/j.amjopharm.2011.02.004.
    1. Marcum ZA, Gellad WF. Medication adherence to multidrug regimens. Clin Geriatr Med. 2012;28(2):287–300. doi: 10.1016/j.cger.2012.01.008.
    1. Stone VE, Hogan JW, Schuman P, Rompalo AM, Howard AA, Korkontzelou C, et al. Antiretroviral regimen complexity, self-reported adherence, and HIV patients’ understanding of their regimens: survey of women in the HER study. J Acquir Immune Defic Syndr. 2001;28(2):124–31.
    1. Atkinson MJ, Petrozzino JJ. An evidence-based review of treatment-related determinants of patients’ nonadherence to HIV medications. AIDS Patient Care STDS. 2009;23(11):903–914. doi: 10.1089/apc.2009.0024.
    1. Maiese E, Malmenas M, Atkinson M. Impact of comorbidities on HIV medication persistence: a retrospective database study using US claims data. J Int AIDS Soc. 2012;15(Suppl 4):18063.
    1. Goulet JL, Fultz SL, Rimland D, Butt A, Gibert C, Rodriguez-Barradas M, et al. Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis. 2007;45(12):1593–1601. doi: 10.1086/523577.
    1. Heaton RK, Clifford DB, Franklin DR, Jr, Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75(23):2087–2096. doi: 10.1212/WNL.0b013e318200d727.
    1. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17(1):3–16. doi: 10.1007/s13365-010-0006-1.
    1. Anema A, Weiser SD, Fernandes KA, Ding E, Brandson EK, Palmer A, et al. High prevalence of food insecurity among HIV-infected individuals receiving HAART in a resource-rich setting. AIDS Care. 2011;23(2):221–230. doi: 10.1080/09540121.2010.498908.
    1. Crystal S, Akincigil A, Sambamoorthi U, Wenger N, Fleishman JA, Zingmond DS, et al. The diverse older HIV-positive population: a national profile of economic circumstances, social support, and quality of life. J Acquir Immune Defic Syndr. 2003;33(Suppl 2):S76–S83. doi: 10.1097/00126334-200306012-00004.
    1. Braithwaite RS, McGinnis KA, Conigliaro J, Maisto SA, Crystal S, Day N, et al. A temporal and dose-response association between alcohol consumption and medication adherence among veterans in care. Alcohol Clin Exp Res. 2005;29(7):1190–1197. doi: 10.1097/01.ALC.0000171937.87731.28.
    1. Kalichman SC, Pellowski J, Kalichman MO, Cherry C, Detorio M, Caliendo AM, et al. Food insufficiency and medication adherence among people living with HIV/AIDS in urban and peri-urban settings. Prev Sci. 2011;12(3):324–332. doi: 10.1007/s11121-011-0222-9.
    1. Huang AR, Mallet L, Rochefort CM, Eguale T, Buckeridge DL, Tamblyn R. Medication-related falls in the elderly: causative factors and preventive strategies. Drugs Aging. 2012;29(5):359–76.
    1. Huang ES, Karter AJ, Danielson KK, Warton EM, Ahmed AT. The association between the number of prescription medications and incident falls in a multi-ethnic population of adult type-2 diabetes patients: the Diabetes and Aging Study. J Gen Intern Med. 2010;25(2):141–6.
    1. Tinetti ME. Clinical practice. Preventing falls in elderly persons. N Engl J Med. 2003;348(1):42–49. doi: 10.1056/NEJMcp020719.
    1. Tinetti ME, Kumar C. The patient who falls: “It’s always a trade-off”. JAMA. 2010;303(3):258–266. doi: 10.1001/jama.2009.2024.
    1. Deandrea S, Lucenteforte E, Bravi F, Foschi R, La Vecchia C, Negri E. Risk factors for falls in community-dwelling older people: a systematic review and meta-analysis. Epidemiology. 2010;21(5):658–668. doi: 10.1097/EDE.0b013e3181e89905.
    1. Kaptoge S, Benevolenskaya LI, Bhalla AK, Cannata JB, Boonen S, Falch JA, et al. Low BMD is less predictive than reported falls for future limb fractures in women across Europe: results from the European Prospective Osteoporosis Study. Bone. 2005;36(3):387–398. doi: 10.1016/j.bone.2004.11.012.
    1. Collin F, Duval X, Le Moing V, Piroth L, Al Kaied F, Massip P, et al. Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS. 2009;23(8):1021–1024. doi: 10.1097/QAD.0b013e3283292195.
    1. Womack JA, Goulet JL, Gibert C, Brandt C, Chang CC, Gulanski B, et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One. 2011;6(2):e17217. doi: 10.1371/journal.pone.0017217.
    1. McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis. 2010;51(8):937–946. doi: 10.1086/656412.
    1. Erlandson KM, Allshouse AA, Jankowski CM, Duong S, Mawhinney S, Kohrt WM, et al. Risk factors for falls in HIV-infected persons. J Acquir Immune Defic Syndr. 2012;61(4):484–489. doi: 10.1097/QAI.0b013e3182716e38.
    1. Valcour V, Paul R, Chiao S, Wendelken LA, Miller B. Screening for cognitive impairment in human immunodeficiency virus. Clin Infect Dis. 2011;53(8):836–842. doi: 10.1093/cid/cir524.
    1. Espino DV, Bazaldua OV, Palmer RF, Mouton CP, Parchman ML, Miles TP, et al. Suboptimal medication use and mortality in an older adult community-based cohort: results from the Hispanic EPESE Study. J Gerontol A Biol Sci Med Sci. 2006;61(2):170–5.
    1. Akgun KM, Gordon K, Pisani M, Fried T, McGinnis KA, Tate JP, et al. Risk factors for hospitalization and medical intensive care unit (MICU) admission among HIV infected veterans. J Acquir Immune Defic Syndr. 2013;62(1):52–9.
    1. Justice A, Modur S, Tate J, Althoff K, Jacobson L, Gebo K, et al. Predictive accuracy of the Veterans Aging Cohort Study (VACS) index for mortality with HIV infection: a north American cross cohort analysis. J Acquir Immune Defic Syndr. 2013;62(2):149–63.
    1. Justice AC, McGinnis KA, Skanderson M, et al. Towards a combined prognostic index for survival in HIV infection: the role of ‘non-HIV’ biomarkers. HIV Med. 2010;11(2):143–51.
    1. Tate JP, Justice AC, Hughes MD, Bonnet F, Reiss P, Mocroft A, et al. The VACS index: an internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS. 2013;27(4):563–72.
    1. Chang CB, Chan DC. Comparison of published explicit criteria for potentially inappropriate medications in older adults. Drugs Aging. 2010;27(12):947–957. doi: 10.2165/11584850-000000000-00000.
    1. Lipton HL, Bero LA, Bird JA, McPhee SJ. The impact of clinical pharmacists’ consultations on physicians’ geriatric drug prescribing. A randomized controlled trial. Med Care. 1992;30(7):646–658. doi: 10.1097/00005650-199207000-00006.
    1. Pugh MJ, Hanlon JT, Wang CP, Semla T, Burk M, Amuan ME, et al. Trends in use of high-risk medications for older veterans: 2004 to 2006. J Am Geriatr Soc. 2011;59(10):1891–1898. doi: 10.1111/j.1532-5415.2011.03559.x.
    1. Steinman MA, Landefeld CS, Rosenthal GE, Berthenthal D, Sen S, Kaboli PJ. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc. 2006;54(10):1516–23.
    1. Korthuis PT, Fiellin DA, Fu R, Lum PJ, Altice FL, Sohler N, et al. Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S83–S90. doi: 10.1097/QAI.0b013e31820bc9a5.
    1. Korthuis PT, Fiellin DA, McGinnis KA, Skanderson M, Justice AC, Gordon AJ, et al. Unhealthy alcohol and illicit drug use are associated with decreased quality of HIV care. J Acquir Immune Defic Syndr. 2012;61(2):171–178. doi: 10.1097/QAI.0b013e31826741aa.
    1. DeLorenze GN, Follansbee SF, Nguyen DP, Klein DB, Horberg M, Quesenberry CP Jr., et al. Medication error in the care of HIV/AIDS patients: electronic surveillance, confirmation, and adverse events. Med Care. 2005;43(9 Suppl):III63–8.
    1. Hellinger FJ, Encinosa WE. Inappropriate drug combinations among privately insured patients with HIV disease. Med Care. 2005;43(9 Suppl):III53–62.
    1. Hellinger FJ, Encinosa WE. The cost and incidence of prescribing errors among privately insured HIV patients. Pharmacoeconomics. 2010;28(1):23–34. doi: 10.2165/11313810-000000000-00000.
    1. Silverberg MJ, Ray GT, Saunders K, Rutter CM, Campbell CI, Merrill JO, et al. Prescription long-term opioid use in HIV-infected patients. Clin J Pain. 2012;28(1):39–46. doi: 10.1097/AJP.0b013e3182201a0f.
    1. Edelman EJ, Gordon K, Becker WC, Goulet JL, Skanderson M, Gaither JR, et al. Receipt of opioid analgesics by HIV-infected and uninfected patients. J Gen Intern Med. 2013;28(1):82–90.
    1. Koeppe J, Armon C, Lyda K, Nielsen C, Johnson S. Ongoing pain despite aggressive opioid pain management among persons with HIV. Clin J Pain. 2010;26(3):190–198. doi: 10.1097/AJP.0b013e3181b91624.
    1. Lum PJ, Little S, Botsko M, Hersh D, Thawley RE, Egan JE, et al. Opioid-prescribing practices and provider confidence recognizing opioid analgesic abuse in HIV primary care settings. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S91–S97. doi: 10.1097/QAI.0b013e31820a9a82.
    1. Onen NF, Barrette EP, Shacham E, Taniguchi T, Donovan M, Overton ET. A review of opioid prescribing practices and associations with repeat opioid prescriptions in a contemporary outpatient HIV clinic. Pain Pract. 2012;12(6):440–448. doi: 10.1111/j.1533-2500.2011.00520.x.
    1. Freiberg MS, Leaf DA, Goulet JL, Goetz MB, Oursler KK, Gibert CL, et al. The association between the receipt of lipid lowering therapy and HIV status among veterans who met NCEP/ATP III criteria for the receipt of lipid lowering medication. J Gen Intern Med. 2009;24(3):334–340. doi: 10.1007/s11606-008-0891-7.
    1. Burkholder GA, Tamhane AR, Salinas JL, Mugavero MJ, Raper JL, Westfall AO, et al. Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients. Clin Infect Dis. 2012;55(11):1550–1557. doi: 10.1093/cid/cis752.
    1. Edelman EJ, Gordon K, Rodriguez-Barradas MC, Justice AC. Patient-reported symptoms on the antiretroviral regimen efavirenz/emtricitabine/tenofovir. AIDS Patient Care STDS. 2012;26(6):312–319. doi: 10.1089/apc.2012.0044.
    1. Armah KA, McGinnis K, Baker J, Gibert C, Butt AA, Bryant KJ, et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis. 2012;55(1):126–136. doi: 10.1093/cid/cis406.
    1. Womack J, Goulet J, Gibert C, Brandt C, Skanderson M, Gulanski B, et al. Physiologic frailty and fragility fracture in HIV infected male Veterans. Clin Infect Dis. 2013;56(10):1498–504.
    1. Marquine MJ, Moore DJ, Gouaux B, Rooney A, Woods SP, Letendre SL, Ellis RJ, Grant I, HNRP group. Higher Veterans Aging Cohort Study (VACS) index scores are associated with concurrent risk of neurocognitive impairment. In: International HIV and Aging Workshop, 2012
    1. Gallagher LP. The potential for adverse drug reactions in elderly patients. Appl Nurs Res. 2001;14(4):220–224. doi: 10.1053/apnr.2001.26788.
    1. Yiu P, Nguyen NN, Holodniy M. Clinically significant drug interactions in younger and older human immunodeficiency virus-positive patients receiving antiretroviral therapy. Pharmacotherapy. 2011;31(5):480–489. doi: 10.1592/phco.31.5.480.
    1. Pau AK, Boyd SD. Recognition and management of significant drug interactions in HIV patients: challenges in using available data to guide therapy. Clin Pharmacol Ther. 2010;88(5):712–719. doi: 10.1038/clpt.2010.130.
    1. Furler MD, Einarson TR, Walmsley S, Millson M, Bendayan R. Polypharmacy in HIV: impact of data source and gender on reported drug utilization. AIDS Patient Care STDS. 2004;18(10):568–586. doi: 10.1089/apc.2004.18.568.
    1. Parenti P, Marconi L, Lupo S. Hepatotoxicity of antiretrovirals in patients with human immunodeficiency virus and viral hepatitis coinfections. J Int AIDS Soc. 2012;15(6):18431.
    1. Green TC, Kershaw T, Lin H, Heimer R, Goulet JL, Kraemer KL, et al. Patterns of drug use and abuse among aging adults with and without HIV: a latent class analysis of a US Veteran cohort. Drug Alcohol Depend. 2010;110(3):208–20.
    1. Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet. 2007;370(9582):185–191. doi: 10.1016/S0140-6736(07)61092-7.
    1. Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16(5):767–774. doi: 10.1097/00002030-200203290-00012.
    1. Baum MK, Rafie C, Lai S, Sales S, Page B, Campa A. Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users. J Acquir Immune Defic Syndr. 2009;50(1):93–99. doi: 10.1097/QAI.0b013e3181900129.
    1. Moore DJ, Blackstone K, Woods SP, Ellis RJ, Atkinson JH, Heaton RK, et al. Methamphetamine use and neuropsychiatric factors are associated with antiretroviral non-adherence. AIDS Care. 2012;24(12):1504–1513. doi: 10.1080/09540121.2012.672718.
    1. Conney AH, Reidenberg MM. Cigarette smoking, coffee drinking, and ingestion of charcoal-broiled beef as potential modifiers of drug therapy and confounders of clinical trials. J Pharmacol Exp Ther. 2012;342(1):9–14. doi: 10.1124/jpet.112.193193.
    1. Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm. 2007;64(18):1917–1921. doi: 10.2146/ajhp060414.
    1. Heppner HJ, Christ M, Gosch M, Muhlberg W, Bahrmann P, Bertsch T, et al. Polypharmacy in the elderly from the clinical toxicologist perspective. Z Gerontol Geriatr. 2012;45(6):473–478. doi: 10.1007/s00391-012-0383-6.
    1. Moore AA, Whiteman EJ, Ward KT. Risks of combined alcohol/medication use in older adults. Am J Geriatr Pharmacother. 2007;5(1):64–74. doi: 10.1016/j.amjopharm.2007.03.006.
    1. Johnson EM, Lanier WA, Merrill RM, Crook J, Porucznik CA, Rolfs RT, et al. Unintentional prescription opioid-related overdose deaths: description of decedents by next of kin or best contact, Utah, 2008–2009. J Gen Intern Med. 2012;28(4):522–9.
    1. Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152(2):85–92. doi: 10.7326/0003-4819-152-2-201001190-00006.
    1. Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC, Bixler D, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008;300(22):2613–2620. doi: 10.1001/jama.2008.802.
    1. Lindsey WT, Stewart D, Childress D. Drug interactions between common illicit drugs and prescription therapies. Am J Drug Alcohol Abuse. 2012;38(4):334–343. doi: 10.3109/00952990.2011.643997.
    1. Willig JH, Westfall AO, Allison J, Van Wagoner N, Chang PW, Raper J, et al. Nucleoside reverse-transcriptase inhibitor dosing errors in an outpatient HIV clinic in the electronic medical record era. Clin Infect Dis. 2007;45(5):658–661. doi: 10.1086/520653.
    1. Edelman EJ, Gordon KS, Lo Re III V, Skanderson M, Fiellin DA, Justice AC. Acetaminophen receipt among HIV-infected patients with advanced hepatic fibrosis. Pharmacoepidemiol Drug Saf. (in review).
    1. Rebeiro P, Althoff KN, Buchacz K, et al. Retention among north American HIV-infected persons in clinical care, 2000–2008. J Acquir Immune Defic Syndr. 2012. [Epub ahead of print].
    1. Fleishman JA, Yehia BR, Moore RD, Korthuis PT, Gebo KA. Establishment, retention, and loss to follow-up in outpatient HIV care. J Acquir Immune Defic Syndr. 2012;60(3):249–259. doi: 10.1097/QAI.0b013e318258c696.
    1. Fournier PO, Savageau JA, Baldor RA. A shift in referral patterns for HIV/AIDS patients. J Fam Pract. 2008;57(2):E1–E9.
    1. Duffus WA, Barragan M, Metsch L, Krawczyk CS, Loughlin AM, Gardner LI, et al. Effect of physician specialty on counseling practices and medical referral patterns among physicians caring for disadvantaged human immunodeficiency virus-infected populations. Clin Infect Dis. 2003;36(12):1577–1584. doi: 10.1086/375070.
    1. Loy A, Townsend L, O’Dea S, Mulcahy F. Management of dyslipidaemia in an HIV-positive cohort. J Int AIDS Soc. 2012;15(6):18128.
    1. Benn PD, Miller RF, Evans L, Minton J, Edwards SG. Devolving of statin prescribing to general practitioners for HIV-infected patients receiving antiretroviral therapy. Int J STD AIDS. 2009;20(3):202–204. doi: 10.1258/ijsa.2008.008273.
    1. Yehia BR, Fleishman JA, Hicks PL, Ridore M, Moore RD, Gebo KA. Inpatient health services utilization among HIV-infected adult patients in care 2002–2007. J Acquir Immune Defic Syndr. 2010;53(3):397–404. doi: 10.1097/QAI.0b013e3181bcdc16.
    1. Yehia BR, Mehta JM, Ciuffetelli D, Moore RD, Pham PA, Metlay JP, et al. Antiretroviral medication errors remain high but are quickly corrected among hospitalized HIV-infected adults. Clin Infect Dis. 2012;55(4):593–599. doi: 10.1093/cid/cis491.
    1. Snyder AM, Klinker K, Orrick JJ, Janelle J, Winterstein AG. An in-depth analysis of medication errors in hospitalized patients with HIV. Ann Pharmacother. 2011;45(4):459–468. doi: 10.1345/aph.1P599.
    1. Rao N, Patel V, Grigoriu A, Kaushik P, Brizuela M. Antiretroviral therapy prescribing in hospitalized HIV clinic patients. HIV Med. 2012;13(6):367–371. doi: 10.1111/j.1468-1293.2011.00977.x.
    1. Fultz SL, Goulet JL, Weissman S, Rimland D, Leaf D, Gibert C, et al. Differences between infectious diseases-certified physicians and general medicine-certified physicians in the level of comfort with providing primary care to patients. Clin Infect Dis. 2005;41(5):738–743. doi: 10.1086/432621.
    1. Waters L, Patterson B, Scourfield A, Hughes A, de Silva S, Gazzard B, et al. A dedicated clinic for HIV-positive individuals over 50 years of age: a multidisciplinary experience. Int J STD AIDS. 2012;23(8):546–552. doi: 10.1258/ijsa.2012.011412.
    1. Chu C, Selwyn PA. An epidemic in evolution: the need for new models of HIV care in the chronic disease era. J Urban Health. 2011;88(3):556–566. doi: 10.1007/s11524-011-9552-y.
    1. Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D. STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72–83.
    1. Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med. 1991;151(9):1825–1832. doi: 10.1001/archinte.1991.00400090107019.
    1. Fitzgerald LS, Hanlon JT, Shelton PS, Landsman PB, Schmader KE, Pulliam CC, et al. Reliability of a modified medication appropriateness index in ambulatory older persons. Ann Pharmacother. 1997;31(5):543–548.
    1. Hilmer SN, Mager DE, Simonsick EM, Cao Y, Ling SM, Windham BG, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med. 2007;167(8):781–787. doi: 10.1001/archinte.167.8.781.
    1. Robbins GK, Lester W, Johnson KL, Chang Y, Estey G, Surrao D, et al. Efficacy of a clinical decision-support system in an HIV practice: a randomized trial. Ann Intern Med. 2012;157(11):757–766. doi: 10.7326/0003-4819-157-11-201212040-00003.
    1. Edelman EJ, Gordon K, Justice AC. Patient and provider-reported symptoms in the post-cART era. AIDS Behav. 2011;15(4):853–61.
    1. Braithwaite RS, Fiellin D, Justice AC. The payoff time: a flexible framework to help clinicians decide when patients with comorbid disease are not likely to benefit from practice guidelines. Med Care. 2009;47(6):610–617. doi: 10.1097/MLR.0b013e31819748d5.
    1. Sigel K, Dubrow R, Silverberg M, Crothers K, Braithwaite S, Justice A. Cancer screening in patients infected with HIV. Curr HIV/AIDS Rep. 2011;8(3):142–152. doi: 10.1007/s11904-011-0085-5.
    1. Singer SR, Hoshen M, Shadmi E, Leibowitz M, Flaks-Manov N, Bitterman H, et al. EMR-based medication adherence metric markedly enhances identification of nonadherent patients. Am J Manag Care. 2012;18(10):e372–e377.
    1. Bonn-Miller MO, Oser ML, Bucossi MM, Trafton JA. Cannabis use and HIV antiretroviral therapy adherence and HIV-related symptoms. J Behav Med. 2012. [Epub ahead of print].
    1. McCance-Katz EF, Rainey PM, Smith P, Morse GD, Friedland G, Boyarsky B, et al. Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine. Am J Addict. 2006;15(1):23–34. doi: 10.1080/10550490500419029.
    1. Corless IB, Lindgren T, Holzemer W, Robinson L, Moezzi S, Kirksey K, et al. Marijuana effectiveness as an HIV self-care strategy. Clin Nurs Res. 2009;18(2):172–193. doi: 10.1177/1054773809334958.
    1. McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict. 2010;19(1):4–16. doi: 10.1111/j.1521-0391.2009.00005.x.
    1. Antoniou T, Tseng AL. Interactions between recreational drugs and antiretroviral agents. Ann Pharmacother. 2002;36(10):1598–1613. doi: 10.1345/aph.1A447.
    1. Gruber VA, McCance-Katz EF. Methadone, buprenorphine, and street drug interactions with antiretroviral medications. Curr HIV/AIDS Rep. 2010;7(3):152–160. doi: 10.1007/s11904-010-0048-2.
    1. Gonzalez A, Mimiaga MJ, Israel J, Andres Bedoya C, Safren SA. Substance use predictors of poor medication adherence: the role of substance use coping among HIV-infected patients in opioid dependence treatment. AIDS Behav. 2013;17(1):168–73.
    1. Arnsten JH, Demas PA, Grant RW, Gourevitch MN, Farzadegan H, Howard AA, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17(5):377–381.
    1. Rosen MI, Black AC, Arnsten JH, Goggin K, Remien RH, Simoni JM, et al. Association between use of specific drugs and antiretroviral adherence: findings from MACH 14. AIDS Behav. 2013;17(1):142–7.
    1. Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr. 2009;52(2):180–202. doi: 10.1097/QAI.0b013e3181b18b6e.
    1. O’Neil CR, Palmer AK, Coulter S, O’Brien N, Shen A, Zhang W, et al. Factors associated with antiretroviral medication adherence among HIV-positive adults accessing highly active antiretroviral therapy (HAART) in British Columbia, Canada. J Int Assoc Physicians AIDS Care (Chic) 2012;11(2):134–141. doi: 10.1177/1545109711423976.
    1. Shuter J, Bernstein SL. Cigarette smoking is an independent predictor of nonadherence in HIV-infected individuals receiving highly active antiretroviral therapy. Nicotine Tob Res. 2008;10(4):731–736. doi: 10.1080/14622200801908190.
    1. Peretti-Watel P, Spire B, Lert F, Obadia Y. Drug use patterns and adherence to treatment among HIV-positive patients: evidence from a large sample of French outpatients (ANRS-EN12-VESPA 2003) Drug Alcohol Depend. 2006;82(Suppl 1):S71–S79. doi: 10.1016/S0376-8716(06)80012-8.
    1. Sullivan PS, Campsmith ML, Nakamura GV, Begley EB, Schulden J, Nakashima AK. Patient and regimen characteristics associated with self-reported nonadherence to antiretroviral therapy. PLoS One. 2007;2(6):e552. doi: 10.1371/journal.pone.0000552.
    1. Hinkin CH, Barclay TR, Castellon SA, Levine AJ, Durvasula RS, Marion SD, et al. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav. 2007;11(2):185–194. doi: 10.1007/s10461-006-9152-0.
    1. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory care quality improvement project (ACQUIP). Alcohol use disorders identification test. Arch Intern Med. 1998;158(16):1789–95
    1. A clinical practice guideline for treating tobacco use and dependence: a US public health service report. The tobacco use and dependence clinical practice guideline panel, staff, and consortium representatives. JAMA. 2000;283(24):3244–54
    1. Allensworth-Davies D, Cheng DM, Smith PC, Samet JH, Saitz R. The short inventory of problems-modified for drug use (SIP-DU): validity in a primary care sample. Am J Addict. 2012;21(3):257–262. doi: 10.1111/j.1521-0391.2012.00223.x.
    1. Yudko E, Lozhkina O, Fouts A. A comprehensive review of the psychometric properties of the Drug Abuse Screening Test. J Subst Abuse Treat. 2007;32(2):189–198. doi: 10.1016/j.jsat.2006.08.002.
    1. Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. A single-question screening test for drug use in primary care. Arch Intern Med. 2010;170(13):1155–1160. doi: 10.1001/archinternmed.2010.140.
    1. Hanlon JT, Schmader KE, Samsa GP, Weinberger M, Uttech KM, Lewis IK, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45(10):1045–1051. doi: 10.1016/0895-4356(92)90144-C.
    1. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616–31.
    1. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163(22):2716–2724. doi: 10.1001/archinte.163.22.2716.
    1. Fick DM, Semla TP. 2012 American Geriatrics Society Beers Criteria: new year, new criteria, new perspective. J Am Geriatr Soc. 2012;60(4):614–615. doi: 10.1111/j.1532-5415.2012.03922.x.
    1. Lam MPS, Cheung BMY. The use of STOPP/START criteria as a screening tool for assessing the appropriateness of medications in the elderly population. Expert Rev Clin Pharmacol. 2012;5(2):187–97.
    1. Hamilton H, Gallagher P, Ryan C, Byrne S, O’Mahony D. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med. 2011;171(11):1013–9.
    1. Gallagher P, O’Mahony D. STOPP (Screening Tool of Older Persons’ potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers’ criteria. Age Ageing. 2008;37(6):673–679. doi: 10.1093/ageing/afn197.
    1. Gallagher PF, O’Connor MN, O’Mahony D. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP/START criteria. Clin Pharmacol Ther. 2011;89(6):845–854. doi: 10.1038/clpt.2011.44.
    1. Alfaro Lara ER, Vega Coca MD, Galvan Banqueri M, Marin Gil R, Nieto Martin MD, Perez Guerrero C, et al. Selection of tools for reconciliation, compliance and appropriateness of treatment in patients with multiple chronic conditions. Eur J Intern Med. 2012;23(6):506–512. doi: 10.1016/j.ejim.2012.06.007.
    1. National Health Service Cumbria. STOPP START Toolkit supporting Medication Review. 2011.
    1. Triant VA. HIV infection and coronary heart disease: an intersection of epidemics. J Infect Dis. 2012;205(Suppl 3):S355–S361. doi: 10.1093/infdis/jis195.
    1. Moore RD, Bartlett JG, Gallant JE. Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLoS One. 2011;6(7):e21843. doi: 10.1371/journal.pone.0021843.
    1. Silverberg MJ, Leyden W, Hurley L, Go AS, Quesenberry CP, Jr, Klein D, et al. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med. 2009;150(5):301–313. doi: 10.7326/0003-4819-150-5-200903030-00006.
    1. Hansen L, Penko J, Guzman D, Bangsberg DR, Miaskowski C, Kushel MB. Aberrant behaviors with prescription opioids and problem drug use history in a community-based cohort of HIV-infected individuals. J Pain Symptom Manage. 2011;42(6):893–902. doi: 10.1016/j.jpainsymman.2011.02.026.
    1. Miaskowski C, Penko JM, Guzman D, Mattson JE, Bangsberg DR, Kushel MB. Occurrence and characteristics of chronic pain in a community-based cohort of indigent adults living with HIV infection. J Pain. 2011;12(9):1004–1016. doi: 10.1016/j.jpain.2011.04.002.
    1. Vijayaraghavan M, Penko J, Bangsberg DR, Miaskowski C, Kushel MB. Opioid analgesic misuse in a community-based cohort of HIV-infected indigent adults. JAMA Intern Med. 2013;14:1–3.
    1. Krashin DL, Merrill JO, Trescot AM. Opioids in the management of HIV-related pain. Pain Physician. 2012;15(3 Suppl):ES157–ES168.
    1. Roy S, Ninkovic J, Banerjee S, Charboneau RG, Das S, Dutta R, et al. Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections. J Neuroimmune Pharmacol. 2011;6(4):442–465. doi: 10.1007/s11481-011-9292-5.
    1. Miller M, Sturmer T, Azrael D, Levin R, Solomon DH. Opioid analgesics and the risk of fractures in older adults with arthritis. J Am Geriatr Soc. 2011;59(3):430–438. doi: 10.1111/j.1532-5415.2011.03318.x.
    1. Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010;170(22):1968–1976. doi: 10.1001/archinternmed.2010.391.
    1. Justice AC, Freiberg MS, Tracy R, Kuller L, Tate JP, Goetz MB, et al. Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis. 2012;54(7):984–994. doi: 10.1093/cid/cir989.
    1. Justice AC, McGinnis KA, Skanderson M, Chang CC, Gibert CL, Goetz MB, et al. Towards a combined prognostic index for survival in HIV infection: the role of ‘non-HIV’ biomarkers. HIV Med. 2010;11(2):143–151. doi: 10.1111/j.1468-1293.2009.00757.x.
    1. Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S22–S32. doi: 10.1097/QAI.0b013e318209751e.
    1. Fiellin DA, Weiss L, Botsko M, Egan JE, Altice FL, Bazerman LB, et al. Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S33–S38. doi: 10.1097/QAI.0b013e3182097537.
    1. Gedmintas L, Solomon DH. HIV and its effects on bone: a primer for rheumatologists. Curr Opin Rheumatol. 2012;24(5):567–575. doi: 10.1097/BOR.0b013e328356d266.
    1. Hughes AK. HIV knowledge and attitudes among providers in aging: results from a national survey. AIDS Patient Care STDS. 2011;25(9):539–545. doi: 10.1089/apc.2011.0026.
    1. Nkansah N, Mostovetsky O, Yu C, Chheng T, Beney J, Bond Christine M, et al. Effect of outpatient pharmacists’ non-dispensing roles on patient outcomes and prescribing patterns. Cochrane Database Syst Rev. 2010;(7):CD000336. .

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj